Affiliation: Children's Healthcare of Atlanta
- Rifaximin for preventing acute graft-versus-host disease: impact on plasma markers of inflammation and T-cell activationMuna Qayed
AFLAC Cancer and Blood Disorders Center, Atlanta, GA 30322, USA
J Pediatr Hematol Oncol 35:e149-52. 2013..This suggests that rifaximin may abrogate bacterial translocation and resultant inflammation, but in alternative donor transplants this does not prevent downstream activation of donor T cells...
- Is the updated Schwartz formula appropriate for assessing renal function prior to hematopoietic stem cell transplantation?Muna Qayed
Aflac Cancer Center and Blood Disorders Service, Emory University and Children s Healthcare of Atlanta, Atlanta, Georgia, USA
Pediatr Blood Cancer 55:199-201. 2010..Agreement between both formulas and DTPA-Tc-(99m) was poor, although the updated formula performed marginally better. The Schwartz formulas do not appear to be accurate enough to be used for pre-transplant kidney function evaluation...
- In vivo T cell costimulation blockade with abatacept for acute graft-versus-host disease prevention: a first-in-disease trialDivya T Koura
Winship Cancer Institute, Emory University, Atlanta, Georgia
Biol Blood Marrow Transplant 19:1638-49. 2013....
- Use of Alefacept for Preconditioning in Multiply Transfused Pediatric Patients with Nonmalignant DiseasesElizabeth O Stenger
AFLAC Cancer and Blood Disorders Center, Children s Healthcare of Atlanta, Emory University, Atlanta, Georgia
Biol Blood Marrow Transplant 21:1845-52. 2015....
- Gemcitabine and docetaxel (GEMDOX) for the treatment of relapsed and refractory pediatric sarcomasLouis Rapkin
Division of Pediatric Hematology Oncology, AFLAC Cancer Center, Children s Healthcare of Atlanta, Emory University, Atlanta, Georgia, USA
Pediatr Blood Cancer 59:854-8. 2012..Patients with relapsed pediatric sarcomas have a poor outcome and are in need of novel effective therapies...
- Comparison of survival at adult versus pediatric treatment centers for rare pediatric tumors in an adolescent and young adult (AYA) population in the State of GeorgiaThomas Cash
Department of Pediatrics, Children s Healthcare of Atlanta, Emory University, Atlanta, Georgia
Pediatr Blood Cancer 62:456-62. 2015..The type of treatment center where 15-21-year-old adolescent and young adult (AYA) patients with rare pediatric tumors achieve their best clinical outcome is unknown...
- Ewing sarcoma with 7;22 translocation: three new cases and clinicopathological characterizationSarah Catherine Shulman
Department of Pathology, Children s Healthcare of Atlanta, Atlanta, Georgia 30322, USA
Fetal Pediatr Pathol 31:341-8. 2012..In comparison to conventional ES with t(11;22) (q24;q12) (EWS-FLI1), the t(7;22) ES variant has a higher propensity for females and children in a younger age group and it occurs more commonly in extraosseous locations...
- Tandem stem cell rescue as consolidation therapy for high-risk neuroblastomaMuna Qayed
AFLAC Cancer Center, Division of Pediatric Hematology Oncology, Emory University and Children s Healthcare of Atlanta, GA 30322, USA
Pediatr Blood Cancer 58:448-52. 2012..We retrospectively describe our institutional experience in using HDC/SCR for patients with high-risk NB, focusing on outcome and acute toxicities...